Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study
Aumolertinib showed potential in treating EGFR-mutated NSCLC patients with LM, with a tolerable safety profile.
Authors
- Kaikai Zhao (ORCID: https://orcid.org/0000-0001-5556-2877)
- Lulu Zhuang
- Defeng Liu (ORCID: https://orcid.org/0000-0001-6751-1399)
- Zhongkai Wei (ORCID: https://orcid.org/0009-0001-1701-1043)
- Xiangjiao Meng (ORCID: https://orcid.org/0000-0003-2737-5905)
- Yankang Li
- Xiaoli Liu
- Xiaoyan Yin (ORCID: https://orcid.org/0000-0001-5103-5500)
- Jinming Yu (ORCID: https://orcid.org/0000-0003-4728-4269)
- Yu Chen (ORCID: https://orcid.org/0009-0007-0669-0830)
Institutions
- Shandong University (CN)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Journal of Neuro-Oncology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1007/s11060-025-04938-w
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- National Natural Science Foundation of China